A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
Stopped early · Phase 1
Conditions studied: Neoplasms, Breast Cancer
In brief
To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Key facts
- Study ID
- NCT02129205
- Run by
- Pfizer
- People needed
- 40
- Starts
- 2014-06-01
- Expected to finish
- 2017-07-01
- Last updated by the study team
- 2019-03-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available
- Previously treated metastatic triple negative breast cancer that expresses Notch3 with at least one measurable lesion
- Adequate bone marrow, renal and liver function
You may not qualify if…
- Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of starting study treatment
- Patients with known symptomatic brain metastases requiring steroids
- Prior treatment with a compound of the same mechanism
Where it is running
- Ronald Reagan UCLA Medical Center, Drug Information Center — Los Angeles, California, United States
- Ronald Reagan UCLA Medical Center — Los Angeles, California, United States
- UCLA Hematology/Oncology — Los Angeles, California, United States
- Westwood Bowyer Clinic — Los Angeles, California, United States
- Santa Monica - UCLA Medical Center & Orthopaedic Hospital — Santa Monica, California, United States
- UCLA Hematology/Oncology - Santa Monica — Santa Monica, California, United States
- The Ohio State University James Cancer Hospital — Columbus, Ohio, United States
- The OSU Investigational Drug Services — Columbus, Ohio, United States
- The OSU Stephanie Spielman Comprehensive Breast Center — Columbus, Ohio, United States
- The Ohio State University Martha Morehouse Medical Plaza — Columbus, Ohio, United States
- South Texas Accelerated Research Therapeutics, LLC (START) — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.